Table 1.
Demographics and characteristics of patients who underwent pre–hematopoietic stem cell transplantation pulmonary function testing at St. Jude Children’s Research Hospital between 1990 and 2009
| Characteristic | All Patients (n = 410) | Patients with Pulmonary Complications (n = 174) | Patients without Pulmonary Complications (n = 236) | P Value |
|---|---|---|---|---|
| Age at transplant, yr | 0.12 | |||
| Mean (SD) | 13.5 (3.81) | 13.8 (3.9) | 13.2 (3.72) | |
| Median (range) | 13.6 (6.2–20.9) | 14.0 (6.2–20.9) | 13.4 (6.2–20.7) | |
| 6–10 | 92 (22) | 34 (20) | 58 (25) | 0.09 |
| 11–18 | 266 (65) | 111 (64) | 155 (65) | |
| 18 to ≤21 | 52 (13) | 29 (16) | 23 (10) | |
| Males | 242 (59) | 100 (58) | 142 (60) | 0.61 |
| Race | 0.20 | |||
| White | 302 (74) | 123 (71) | 179 (76) | |
| African American | 66 (16) | 32 (18) | 34 (14) | |
| Hispanic | 33 (8) | 18 (10) | 15 (6) | |
| Other | 9 (2) | 1 (1) | 8 (4) | |
| Diagnosis | 0.77 | |||
| ALL | 117 (29) | 50 (29) | 67 (29) | |
| AML | 115 (28) | 53 (30) | 62 (27) | |
| CML | 42 (10) | 20 (11) | 22 (9) | |
| Lymphoma | 22 (5) | 7 (4) | 15 (6) | |
| MDS | 35 (9) | 13 (7) | 22 (9) | |
| Solid tumors | 21 (5) | 6 (3) | 15 (6) | |
| Hematologic disorders | 49 (12) | 20 (13) | 29 (12) | |
| Immunologic disorders | 9 (2) | 5 (3) | 4 (2) | |
| Donor type | 0.02 | |||
| Matched-related | 136 (33) | 44 (25) | 92 (39) | |
| Mismatched-related | 16 (4) | 6 (4) | 10 (4) | |
| Matched-unrelated | 143 (35) | 62 (36) | 81 (34) | |
| Mismatched-unrelated | 32 (8) | 18 (10) | 14 (6) | |
| Haploidentical | 83 (20) | 44 (25) | 39 (17) | |
| Product type | 0.23 | |||
| HPC-M | 319 (78) | 130 (75) | 189 (80) | |
| HPC-A | 91 (22) | 44 (25) | 47 (20) | |
| CMV D/R status | 0.14 | |||
| Donor+/recipient+ | 126 (31) | 63 (36) | 63 (27) | |
| Donor+/recipient– | 64 (16) | 24 (14) | 40 (17) | |
| Donor–/recipient+ | 69 (17) | 31 (18) | 38 (16) | |
| Donor–/recipient– | 151 (36) | 56 (32) | 95 (40) | |
| TBI | 0.15 | |||
| Yes | 293 (72) | 131 (75) | 162 (69) | |
| No | 117 (28) | 43 (25) | 74 (31) | |
| Conditioning | 0.70 | |||
| Myeloablative | 335 (82) | 144 (83) | 191 (81) | |
| RIC | 75 (18) | 30 (17) | 45 (19) | |
| T-cell depletion | <0.001 | |||
| Yes | 182 (44) | 98 (56) | 84 (36) | |
| No | 228 (56) | 76 (44) | 152 (64) | |
| Acute GVHD | 0.009 | |||
| Yes | 216 (53) | 105 (60) | 111 (47) | |
| No | 194 (47) | 69 (40) | 125 (53) | |
| Acute GVHD grade | <0.0001 | |||
| Grade I–II | 115 (28) | 41 (24) | 74 (31) | |
| Grade III–IV | 101 (25) | 64 (36) | 37 (16) | |
| None | 194 (47) | 69 (40) | 125 (53) | |
| Chronic GVHD | 0.06 | |||
| Yes | 85 (20) | 44 (25) | 41 (17) | |
| No | 325 (80) | 130 (75) | 195 (83) | |
| Chronic GVHD grade | 0.09 | |||
| Limited | 43 (10) | 20 (11) | 23 (10) | |
| Extensive | 42 (10) | 24 (14) | 18 (7) | |
| None | 325 (80) | 130 (75) | 195 (83) |
Definition of abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; CMV D/R = cytomegalovirus donor/recipient; GVHD = graft-versus-host disease; HPC-M/A = human progenitor cells-marrow/apheresis; MDS = myelodysplastic syndrome; RIC = reduced-intensity conditioning; TBI = total body irradiation.
Note: Unless otherwise indicated, data represent number (%) of patients.